Post-translational regulation of RORγt-A therapeutic target for the modulation of interleukin-17-mediated responses in autoimmune diseases

被引:51
|
作者
Rutz, Sascha [1 ]
Eidenschenk, Celine [2 ]
Kiefer, James R. [3 ]
Ouyang, Wenjun [4 ]
机构
[1] Genentech Inc, Dept Canc Immunol, 1 DNA Way, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA
[4] Amgen Inc, Dept Inflammat & Oncol, San Francisco, CA 94080 USA
关键词
Retinoic acid-related orphan receptor; gamma; Nuclear receptor; Interleukin-17; Inverse agonist; Ubiquitinylation; Posttranslational regulation; ORPHAN NUCLEAR RECEPTOR; LONG NONCODING RNAS; T(H)17 CELL-DIFFERENTIATION; MEDIATED TRANSCRIPTIONAL ACTIVATION; AMINO-TERMINAL DOMAINS; LIGAND-BINDING DOMAIN; REV-ERB-ALPHA; RETINOIC ACID; TH17; CELLS; THYMOCYTE SURVIVAL;
D O I
10.1016/j.cytogfr.2016.07.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Retinoic acid-related orphan receptor gamma t (ROR gamma t) is a nuclear receptor, which is selectively expressed by various lymphocytes. RORyt is critical for the development of secondary and tertiary lymphoid organs, and for the thymic development of the T cell lineage. ROR gamma t has been extensively studied as the master transcription factor of IL-17 expression and Th17 cells, which are strongly associated with various inflammatory and autoimmune conditions. Given its essential role in promoting pro-inflammatory responses, it is not surprising that the expression of ROR gamma t is tightly controlled. By its nature as a nuclear receptor, ROR gamma t activity is also regulated in a ligand-dependent manner, which makes it an attractive drug target. In addition, multiple post-translational mechanisms, including post translational modifications, such as acetylation and ubiquitinylation, as well as interactions with various co-factors, modulate ROR gamma t function. Here we attempt a comprehensive review of the post-translational regulation of ROR gamma t, an area that holds the potential to transform the way we target the ROR gamma t/IL-17 pathway, by enabling the development of safe and highly selective modulators of ROR gamma t activity. (C) 2016 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 17 条
  • [1] Post-translational Regulation of GLT-1 in Neurological Diseases and Its Potential as an Effective Therapeutic Target
    Peterson, Allison R.
    Binder, Devin K.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2019, 12
  • [2] Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease
    Kuwabara, Taku
    Matsui, Yukihide
    Ishikawa, Fumio
    Kondo, Motonari
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (03)
  • [3] Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells
    Rutz, Sascha
    Kayagaki, Nobuhiko
    Phung, Qui T.
    Eidenschenk, Celine
    Noubade, Rajkumar
    Wang, Xiaoting
    Lesch, Justin
    Lu, Rongze
    Newton, Kim
    Huang, Oscar W.
    Cochran, Andrea G.
    Vasser, Mark
    Fauber, Benjamin P.
    DeVoss, Jason
    Webster, Joshua
    Diehl, Lauri
    Modrusan, Zora
    Kirkpatrick, Donald S.
    Lill, Jennie R.
    Ouyang, Wenjun
    Dixit, Vishva M.
    NATURE, 2015, 518 (7539) : 417 - 421
  • [4] Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells
    Sascha Rutz
    Nobuhiko Kayagaki
    Qui T. Phung
    Celine Eidenschenk
    Rajkumar Noubade
    Xiaoting Wang
    Justin Lesch
    Rongze Lu
    Kim Newton
    Oscar W. Huang
    Andrea G. Cochran
    Mark Vasser
    Benjamin P. Fauber
    Jason DeVoss
    Joshua Webster
    Lauri Diehl
    Zora Modrusan
    Donald S. Kirkpatrick
    Jennie R. Lill
    Wenjun Ouyang
    Vishva M. Dixit
    Nature, 2015, 518 : 417 - 421
  • [5] Current therapeutic leads for the treatment of autoimmune diseases: stem cell transplantation and inhibition of post-translational modifications of autoantigens
    Papanastasiou, Anastasios D.
    Chatzantoni, Kokona
    Mouzaki, Athanasia
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (10) : 1255 - 1265
  • [6] IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases:: regulation of T helper 1/T helper 2 responses
    Haskó, G
    Szabó, C
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (06) : 1295 - 1304
  • [7] Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells
    Singh, Bhagirath
    Schwartz, Jordan Ari
    Sandrock, Christian
    Bellemore, Stacey M.
    Nikoopour, Enayat
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2013, 138 : 591 - 594
  • [8] Post-translational modifications of nuclear co-repressor RIP140: A therapeutic target for metabolic diseases
    Huq, M. D. Mostaqul
    Gupta, Pawan
    Wei, Li-Na
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (04) : 386 - 392
  • [9] Kv1.3 channels: therapeutic target for T cell-mediated autoimmune diseases
    Beeton, C.
    Wulff, H.
    Standifer, N. E.
    Mullen, K. M.
    Azam, P.
    Kolski-Andreaco, A.
    Wei, E.
    Grino, A.
    Counts, D. R.
    Wang, P. H.
    LeeHealey, C. J.
    Andrews, B. S.
    Pennington, M. W.
    Knaus, H. G.
    Nepom, G. T.
    Gutman, G. A.
    Calabresi, P. A.
    Chandy, K. G.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S148 - S148
  • [10] Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
    Beeton, Christine
    Wulff, Heike
    Standifer, Nathan E.
    Azam, Philippe
    Mullen, Katherine M.
    Pennington, Michael W.
    Kolski-Andreaco, Aaron
    Wei, Eric
    Grino, Alexandra
    Counts, Debra R.
    Wang, Ping H.
    LeeHealey, Christine J.
    Andrews, Brian S.
    Sankaranarayanan, Ananthakrishnan
    Homerick, Daniel
    Roeck, Werner W.
    Tehranzadeh, Jamshid
    Stanhope, Kimber L.
    Zimin, Pavel
    Havel, Peter J.
    Griffey, Stephen
    Knaus, Hans-Guenther
    Nepom, Gerald T.
    Gutman, George A.
    Calabresi, Peter A.
    Chandy, K. George
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (46) : 17414 - 17419